Teva Pharmaceutical Industries Ltd (TEVA) 2022 Q4 法說會逐字稿

Good day, and thank you for standing by. Welcome to the Teva's Fourth Quarter and Full Year 2022 Earnings Call. (Operator Instructions)

Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Ran Meir, Senior Vice President, Head of Investor Relations. Please go ahead.

Thank you, Nadia. Thank you, everyone, for joining us today. We hope you have had an opportunity to review our press release, which was issued earlier this morning. A copy of the press release as well as the copy of the slides being presented on this call can be found on our website at tevapharm.com. Please review our forward-looking statements on Slide 2. Additional information regarding these statements and our non-GAAP financial measures is available on our earnings release and in our SEC Form 10-K and 10-Q.

To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's 2022 results and business performance, recent events and priorities going forward. Our CFO, Eli Kalif, will follow up by reviewing the financial results in more detail, including our 2022 financial outlook. Joining Richard and Eli on the call today is Sven Dethlefs, Head of North America business. who will be available during the question-and-answer session that will follow the presentation. Please note that today's call will run approximately 1 hour.

And with that, I will now turn the call over to Richard. Richard, if you would, please?

Thank you, Ran, and welcome, everyone. I'm excited to be here today, and I'd like to start by saying it was great meeting many of you in San Francisco at JPMorgan last month. And I look forward to getting to know Teva shareholders, investors and analysts, so that you can have an open dialogue going forward. I'm excited to be here because there's a lot of opportunity at Teva. The team has done a tremendous work to get the company back to a solid foundation. And now there's an opportunity to get back to growth.

Before I start my review of Teva's 2022 results and discuss our guidance for 2023. I would like to update you that I've already initiated a strategic review process with my leadership team. Our teams are already hitting the ground running, and we are working hard on analyzing some of the core strategic questions, how the segments we operate are going to evolve over time, and we understand what options we have. It's going to be a very clear, purposeful strategy with real intent behind it. Every function, every dollar should follow that strategy going forward. Once the work is done around midyear, I'll come back with the team and we'll present that to the market.

Now let's move on to some highlights for 2022. We ended 2022 with revenues of $14.9 billion, and adjusted EBITDA of $4.6 billion. GAAP diluted loss per share was $2.12, and non-GAAP diluted earnings per share was $2.52. You should note that our revenues were still affected by the strengthening of the U.S. dollar during the fourth quarter, and we therefore still seeing significant headwinds from exchange rate movements on our revenues. We had a net impact of $780 million for the full year compared to 2021.

Free cash flow in 2022 was $2.2 billion, and we continue to reduce our debt in accordance with our strategic targets. Net debt is now down to $18.4 billion.

Moving to the business overview. AUSTEDO, our leading brand is growing very nicely, up 20% year-over-year, and AJOVY also grew across all 3 geographies, U.S., Europe and International markets. I'll further discuss these 2 products in a few minutes.

We've also seen nice growth in our generics and OTC revenues in Europe, reflecting our strong position there and also some successful product launches. We've also seen good growth in Generics and OTC on international markets through a combination of volume growth as well as price adjustments to address inflation. So good to see 9% growth in Europe and 5% in international in local currency terms.

We're also excited about the progress we're making on our pipeline. We recently initiated the Phase 3 trial of subcutaneous long-acting Olanzapine for Schizophrenia, together with UZEDY, our risperidone long-acting product, which I'll talk about in a few minutes. We're developing an exciting franchise for patients suffering from schizophrenia.

After the nationwide opioid litigation settlement we announced last month that we are moving on with the settlements after receiving poor support from the state of (inaudible). We already stated with 49 of the 50 states and the sign-on process for the state subdivisions has begun. And given the very positive response from the states, we remain optimistic that the settlements will give a similar support for that.

Moving on to the next slide to look at our revenue and how it's developing. Overall, you'll see a fairly stable business with the portfolio of products and geographical spread that are well balanced. I'd like to point out that in 2022, Q4 was the strongest quarter in terms of revenue similar to previous years. If you exclude the impact of FX, revenues in Q4 2022 were actually up 1% compared to the fourth quarter of 2021. So in local currency terms, we had a nice single-digit growth in both Europe and international markets.

Moving to the next slide and expand on the comment I just made on Europe. It's a market that I'm very positive about. Europe is good, stable business to Teva. In markets like Europe, if you have a good pipeline, good go-to-market model, the business is predictable and it can drive continued growth. And we believe we have all of those elements in our European business. We have a good portfolio, good pipeline and strong leadership in many of the markets. And this also supports a good margin profile, as you can see from the slide. And this is all playing out well. As you can see, revenues grew in Europe in the fourth quarter, 4% in local currency terms, which we're very pleased about.

Now moving on to AUSTEDO, our next slide. Quarter 4 was a record quarter for AUSTEDO as we continue to see strong growth in both total and new prescriptions. Revenues grew 20% for the full year and 22% in the fourth quarter. I'm happy to see strong continued development with nice increases in both revenue and the numbers of prescriptions. So all-in-all, the trajectory looks positive. Eli will elaborate on it when we talk about our 2023 outlook.

Now to better understand the potential of AUSTEDO, I'd like to take a look at the next slide. As you can see, there are approximately 785,000 patients suffering from Tardive Dyskinesia in the U.S. But unfortunately, only 15% of these patients are diagnosed and then even more disappointing 5% are getting treatment. So clearly, there is a lot of unmet need. And of course, we're working hard to broaden that base, making sure they can benefit -- the benefit of the product reaches more patients who need this therapy. This will drive increased prescriptions and also presents a significant long-term growth potential for AUSTEDO.

Now moving onto AJOVY. Full year, our revenues grew more than 20% globally. This was despite the foreign exchange headwinds we faced in Europe and international markets. Now I think AJOVY is a great example of Teva's strong commercial and execution capabilities. As you know, AJOVY was not first-to-market in the U.S. and Europe, but we're still capturing really strong market share and actually second in Europe. So that's been very impressive and another proof point to me that the innovative and commercial go-to-market capabilities of Teva are strong.

What we're seeing now in the U.S. is really about slow growth is around the injectable anti-CGRP therapies. And while most of the growth in migraine space is driven by the oral therapies. Outside the U.S., we expect AJOVY to benefit from continued patient growth and launches in additional countries in Europe and international markets.

Now moving on to the pipeline, the next slide, please. In my 6 weeks of Teva, I've met with R&D teams. And I have to say that I'm very impressed with the capabilities and the people we have. I was also pleasantly surprised by our innovative pipeline. We plan on sharing more details on it when we discuss our updated strategy throughout this year.

Now let me highlight a couple of exciting assets that are under regulatory review. Firstly, on biosimilar to Humira is expected to launch in July 2023, pending FDA approval, which I'll talk about in a bit more detail in a few minutes. I'm also happy that the FDA has accepted for review the BLA for our biosimilar STELARA, and we anticipate that the review will be completed in the second half of this year.

Moving to our innovative medicines pipeline. As I said before, we are building a strong foundation for the schizophrenia franchise. UZEDY, an important product for patients suffering from schizophrenia which I will elaborate on in the next slide; and Olanzapine long acting, another exciting prospect in the treatment of schizophrenia. We recently moved into a Phase 3 trial.

With olanzapine and (inaudible) steady represent complementary approaches to schizophrenia patient management by addressing unmet needs in the long-acting market. And together with AUSTEDO which treat Tardive Dyskinesia, a side effect for schizophrenia treatment. We're building a strong franchise for schizophrenia therapies.

So moving on to the next slide to talk about UZEDY. As you know, we have resubmitted the file to the FDA for review and expect to have a decision in the first half of this year. So just to frame the market landscape, there are approximately 2 million treated schizophrenia patients in the U.S. and approximately 10% of them receive long-acting injectable products. And this long-acting category is growing steadily. In terms of sales, the overall schizophrenia long-acting market in 2021 was estimated to be $4 billion.

Now relative to other therapies in the market, UZEDY, our product, will have more patient-friendly injection mechanism, which is subcutaneous, a small needle and is lower volume, and it comes in a ready-to-use prebuilt syringe. Basically, an easy and effective way to get to your therapy. And we are very much looking forward to bringing these benefits to the patients who are suffering from schizophrenia, and we need stable therapy to avoid relapses. Given these profile advantages, we're happy with UZEDY, we're targeting about a 20% market share over time.

Now let's talk about Humira, which I know has been getting a lot of attention recently and is the largest product in the history to face biosimilar competition with annual revenues of over $17 billion. Now based on our most recent updates from our partner, Alvotech, we're pairing for the launch on the first of July this year. The FDA has confirmed that the target date for the decision on Alvotech's application is April 13 of this year.

The FDA has also confirmed that the data provided by Alvotech is sufficient to support a determination of interchangeability. And approval, of course, requires a satisfactory outcome from the upcoming facility inspection or reinspection, should I say, which is scheduled for March. It should be noted that while we are still waiting for the approval in the U.S., Alvotech's biosimilar of Humira is currently being marketed in 17 countries around the world, including Canada and numerous markets across Europe.

Now to be clear, we have risk-adjusted its contribution to our 2023 guidance, similar to the way we risk adjust other significant launches in the U.S. market. That said, we believe biosimilar to Humira, like other biosimilar products will continue to be an important product in our portfolio beyond 2023.

Now moving on to the next slide. ESG is every one's business at Teva. Let me be clear about that. The Board and the executive management team firmly believe that ESG is critical and inseparable to our long-term sustainability and success. Over the last few teams -- the last few years, the team has worked hard to lay strong ESG foundations and formalize our ESG strategy. We have set ambitious and meaningful targets that are tied to our business, enhance the reporting and disclosures and strengthen our governance. Our ESG strategy focused on advancing health and equity through our medicines, minimizing the impact of our operations and products on the planet and dedicating the company to quality ethics and transparency.

So now let's talk about our 2027 long-term targets. First of all, I'd like to say, as I said in the beginning, I do think the management team has done a great job over the last few years to get the company back to a solid foundation. As we define our strategy going forward over the next few months, we will look for the opportunities to prioritize and to reallocate the best position to have long-term growth and success. We'll come back and share that with you with our new strategy around midyear (inaudible) and very much looking forward to it. But with regard to these long-term financial targets, these will remain in place.

And with that, I will hand over to Eli to walk you through the financials.

Thank you, Richard, and good morning and good afternoon to everyone. I'll begin my review of our 2022 financial results with my main focus being on the fourth quarter performance. This will be followed by an introduction to our 2023 GAAP outlook and some of the important assumptions behind it.

Beginning on Slide 16. I would like to start with our Q4 GAAP performance. Revenues in the fourth quarter of 2022 were $3.9 billion, representing a decrease of 5% or increase of 1% in local currency terms compared to the fourth quarter of 2021. This increase was mainly due to higher revenue from ANDA generic products in our Europe segment, AUSTEDO and AJOVY, partially offset by lower revenues from generics products and certain respiratory products in our North America segment as well as COPAXONE.

In Q4 2022, we recorded a GAAP operating loss of $855 million compared to operating income of $78 million in Q4 2021, with a net loss of $1.2 billion compared to $159 million in Q4 2021. Any GAAP loss per share of $1.10 compared to $0.14 in the same period a year ago. GAAP operating loss, net loss and loss per share were mainly due to goodwill impairment charges in the fourth quarter of 2022, partially offset by lower legal settlement and loss contingencies. The goodwill impairment charges were mainly related to exchange rate fluctuations in our international markets and update projections in our Teva [staffing] business.

The strengthening of the U.S. dollar versus other currencies during the fourth quarter of 2022, including hedging effects negatively impacted our revenue and GAAP operating income by $270 million and $132 million, respectively, compared to the fourth quarter of 2021.

Turning to Slide 17. You can see that the total non-GAAP adjustment in the fourth quarter of 2022 were $2 billion, and this is versus $1 billion in Q4 2021. The most notable non-GAAP adjustment was a goodwill impairment charges of $1.3 billion, which I just mentioned.

Now moving to Slide 18 for a review of our non-GAAP performance. I've already discussed our fourth quarter revenues, which totaled approximately $3.9 billion. Annual revenues were $14.9 million, a decrease of 6% or 1% in local currency terms compared to 2021. For the full year, we saw the same trend regarding U.S. dollar appreciation, which including hedging effects negatively impacted revenues by $780 million compared to 2021.

Now let's move down to the P&L and look at the margin. Our non-GAAP gross profit margin was 54.2% compared to 56.1% in Q4 2021. The decrease in non-GAAP gross profit margin was mainly due to the higher revenue with the lower profitability from the ANDA in our North America segment, partially offset by higher revenue from AUSTEDO in our North America segment and a favorable mix of generic products in our Europe segment.

Our non-GAAP operating margin in Q4 '22 was 29.1% versus 30.4% in Q4 '21. This decrease was mainly driven by a lower gross profit margin, I mentioned above, partially offset by lower operating expenses, which I will discuss in the next slide. 2022 for year non-GAAP operating margin was 27.7%, similar levels as in 2021. We ended the quarter with a non-GAAP earnings per share of $0.71 compared to $0.77 in Q4 2021, mainly due to the negative impact from foreign exchange fluctuations and the lower gross profit, partially offset by lower operating expenses as well as lower tax rate.

Now let's take a look at our spend base on Slide 19. As you can see, our quarterly spend base declined by $97 million and increased by $38 million net of FX. For the full year 2022, our total spend base declined by [$691] million or $174 million net of FX, annual decrease in our spend base was due to a lower cost of goods sold related to a lower annual revenue as well as ongoing active management of operating expenses. Looking ahead to 2023, we expect the overall spend base to remain at the level of $11 billion as we continue with our ongoing efforts to transform our global operational networks and ongoing active management of operating expenses.

If you look at Slide 20, we continue our journey to improve margins by reaching 28% operating margin by end of 2023. Despite of some of the macroeconomic headwinds related to the inflationary pressures, and while we continue to face these pressures, our ongoing efforts to reduce and optimize our cost of goods sold and operating expenses are expected to continue to help us partially mitigate this global macroeconomic headwinds. As Richard mentioned earlier, we continue to target 30% operating margin by end of 2027.

Turning to free cash flow on Slide 21. Our free cash flow in the fourth quarter of 2022 was $1.1 billion, the increase in our free cash flow in the fourth quarter of 2022 compared to the fourth quarter of 2021 resulted mainly from the sale of accounts receivable under a U.S. securitization facility entered into November 2022, partially offset by changes in working capital terms.

For the full year 2022, free cash flow was $2.2 billion, an increase of 2% compared to 2021 and on the high end of our 2022 guidance. Free cash flow in the 2022 was largely affected by the sale of accounts receivable under a new U.S. securitization facility entered in November 2022, partially offset by an increase in inventory levels, lower proceeds from divestitures of business and other assets as well as higher payment of legal settlement in connection with office litigations.

Turning to Slide 22. Our progress continued in terms of reducing down our debt. The net debt at the end of Q4 2022 was $18.4 billion, compared to $20.9 billion at the end of 2021. The decrease in our gross debt in 2022 was mainly due to the debt repayment, partially offset by exchange rate fluctuation. The decrease in our net debt was mainly due to our free cash flow generation during the year. Our net debt-to-EBITDA ratio continued to decrease coming in 4x for Q4 2022.

Looking at Slide 23. Debt reduction continues to be our primary focus. As you can see, we have made significant progress in the last 6 years as we had committed to reduce the level of the debt we had on our balance sheet. During these 6 years, we've paid back approximately $20 billion to our bondholders, including interest payments and we expect our net debt to further decline as we continue to make progress towards 2027 long-term targets.

Turning to Slide 24, which represents our upcoming debt maturities. If you recall, we did a $5 billion SLB refinancing to address the '22, '23 and '24 maturities back in November 2021. We continue to assess market conditions for opportunities to refinance upcoming maturities. Given the interest rate environment, we expect it to result in a higher financial expenses in 2023, which I will discuss in a few moments.

Looking at the cash conversion on Slide 25. We established a target of 80% by end of 2023. In 2022, we made further progress on this. As we keep focusing on our net working capital enhancements, our efforts to optimize our working capital turns in light of our revenue mix is key for our liquidity. We're really happy to see that it came in at 80%, up from 77% in 2021. As Richard mentioned earlier, we'll continue to manage our business and working capital with a focus on generating cash to earnings at this level.

Now let's turn our attention to our 2023 non-GAAP outlook, which we are introducing for the first time today. Here in Slide 26, you will find the 5 main components of our outlook: revenues, operating income, adjusted EBITDA, earnings per share and free cash flow as well as additional components, including expected revenue range for key products. Our company worked hard throughout 2022, navigating and addressing the ongoing impact of the geopolitical and macroeconomic headwinds. We expect this volatile environment in the markets to continue in 2023 based on leading global financial institutions forecast.

With this in mind, we begin with 2023 total revenue, which we expect to be between $14.8 billion and $15.4 billion. This is very much in line with our revenue levels in 2022. We expect continued momentum of AUSTEDO with a total annual revenue to grow to approximately $1.2 billion or 24% in 2023. Furthermore, AJOVY is expected to benefit from continued patient growth in the U.S., Europe and international markets. Global sales for AJOVY are expected to be approximately $400 million in 2023.

We have factored into our guidance the continued erosion of global COPAXONE revenue, which we expect to decline during 2023 to approximately $500 million. The majority of the decline is expected in the U.S. The expected ongoing growth of AUSTEDO and AJOVY is greater than the offset effect by the decline in COPAXONE sales. Our non-GAAP operating income is expected to be between $4 billion and $4.4 billion, and our non-GAAP adjusted EBITDA is expected to be between $4.5 billion and $4.9 billion.

As discussed earlier, we continue to explore opportunities to refinance the upcoming debt maturities to align our debt maturity profile for the coming years with our core operational performance. There could be a meaningful step up in our finance expenses if we were to pursue any refinancing due to the higher interest rate environment. We expect an increase of approximately $100 million reaching $1 billion in 2023.

Looking at our tax rate in 2022, our non-GAAP tax rate was 11.7%. As we look ahead to 2023, we expect our tax rate to be in the range of 14% to 17%. You might recall that our non-GAAP tax rate in 2022 was below our initial guidance as it was mainly affected by realization of the loss related from investment in our -- one of our U.S. subsidiaries. This expected increase in our finance expenses, tax rate expected to have significant impact on our EPS 2023 outlook in comparison to 2022. This brings us to the expected earnings per share in the range of $2.25 to $2.55, using a share count of approximately 1.1 billion shares.

2023 free cash flow is expected to be in the range of $1.7 billion to $2.1 billion This guidance reflects our expected higher plant expenses, which I have outlined before as well as increased legal expenses related to the nationwide opioid settlement. As you know, we do not provide quarterly guidance, but I thought it would be helpful to share with you how we are thinking about the progression the -- both revenue and earnings throughout the year.

Based on our expectations to date, we anticipate that similar to the progress in 2022, the first quarter will be the loss of our 4 quarters of revenue and earnings with a gradual pickup in the second quarter. I hope this color will assist you with your modeling. This concludes our review of Teva's results for the fourth quarter and fiscal year 2022.

And now I will hand it back to Richard for a summary.

Thanks, Eli. Before moving to the Q&A, I'd just like to summarize some key points. So I'm happy with the progress that has been made so far, and I want to congratulate the entire team, all my colleagues across the globe on a solid Q4 and full year 2022.

AUSTEDO and AJOVY continued to drive growth. And as I mentioned before, there is still a large unmet need that will drive growth in the future for AUSTEDO in the U.S. and AJOVY continues to see good traction, particularly in Europe and international markets.

We have strong performance in Europe and international markets and our European business is steadily growing with leadership positions in most markets. We have an exciting pipeline across innovative medicines, biosimilars and generics. And these interesting and differentiated assets will set us up for future growth. We remain committed to our long-term financial goals around growth, improving margins and driving down debt. And finally, I look forward to sharing with you sometime in mid-year our updated strategy to ensure how we can position Teva for long-term success.

With that, thank you for listening. I'll now hand you back to the operator for Q&A.

(technical difficulty)

Now we'll start the Q&A session. The first question comes now from the line of Umer Raffat Evercore ISI.

Umer here. A couple of things, if I may. First, on guidance, I think there's a little bit of confusion on how much Humira is in the number. And I guess, said differently, what people are really focused on is, is it still a growth year off of '22, if there was no Humira. That was first. Second, I wanted to touch up on the TL1A program a little bit. Could you tell us if the asthma trial was a complete zero. I know it was terminated.

And also for the IBD Phase 2 you initiated in August last year, how is the recruiting tracking? And could you be in a position to take an interim analysis on 14-week data perhaps later in 2022, which could inform a more accelerated Phase 3 start, just given how competitive this could get.

Umer, thanks for the question. So on guidance, as I mentioned, we do have Humira that is risk adjusted. And I think your question was, if we don't have Humira, will we still be able to drive growth. And I think I'll -- Eli contribute, but what I would say is we have a number of opportunities to drive revenue in 2023. Humira is part of that. But obviously, we also talked about AUSTEDO, we've also got UZEDY, and we have other pipeline products that we haven't highlighted in this call. It is an important part, but we've risk adjusted it to take into account the uncertainty. But maybe I'll let Eli give some more color.

Yes, Umer, you see the range that we have there, and you can look on the midpoint versus the '22 revenue if you see kind of modest increase, then I will say that -- to echo Richard, what he mentioned, Humira is in the guidance and is risk adjusted. And we have few other elements that might potentially hedge that element if it will not come through.

Thanks, Eli. And then going on to your question on the TL1A. It was sort of glad you put up because I think this highlights some of the interesting assets we do have in our pipeline, which will, as I said, fully discussed in midyear when we do a review of our pipeline and let people see some of the things that I'm excited about.

But to try and answer your question, we have initiated a clinical Phase 2 basket trial that started in August of 2022 in ulcerative colitis and Crohn's disease. So that is underway. I can't give much more information than that. But as I said, midyear, we'll probably be able to go into a lot more detail on the clinical development plans for that asset and some of the others.

And the next question comes from the line of Gary Nachman from BMO.

Okay. Great. So Richard, you have a clear strategy of building out your biosimilar capabilities while a competitor decided to sell off its biosimilar.

(technical difficulty)

That's okay. So I'll start over. So you have a clear strategy of building out your biosimilar capabilities while a competitor decided to sell off its biosimilar business. So how much more critical mass do you need to maximize value in that market long term? And then how do you see markets formation, particularly with Humira biosimilars and the benefit of having an interchangeable available. How does that impact your payer discussions? If you could give us some color on that.

And then just on the generics business, Richard, will you be able to get back to $1 billion per quarter or so in North America, that was previously a target the company had. Just talk about some of the dynamics there, and you think you'll be able to stabilize that business? Will it continue to decline, maybe talk a little bit at a high level about the pipeline and maybe how that could return that business to growth over time.

Thanks, Gary. Thanks for your questions. And sticking with us on the technical issues. So on the biosimilar one, I'll take a stab on these questions and also maybe tag team it with some of my colleague.

So on the biosimilar, I don't want to comment on other companies' strategies. We're focused on our own. But what I would say is, and I've got a history here, I do believe in the biosimilar opportunity in the market, and I think it's significant. And I think it's significant in the U.S., and I think it's significant in Europe and the rest of the world. I do believe it has an opportunity to drive growth over the short, medium and potential long term. I do think to answer one of your parts of your question, it does require you to have a deep pipeline. And I think one of the things is you've got to be able to continuously launch biosimilar products as they become available.

And so I think the team have done a good job here in building out a pipeline. We want to make sure we continue to do that. We want to make sure we continue to have a geographical spread of that pipeline as we go forward. But yes, I see biosimilars as an opportunity to drive growth in the short and medium term.

Now when we talk about the market formation of biosimilars Humira. What I would say is let's not forget the size of the price here. This is over $17 billion in the U.S. I was part of the introduction of Humira into the European market. So this is a big asset where I think payers and health care authorities can garner some significant savings. I think that's going to bear out over time.

I'll let Sven talk a bit about how quickly that can happen. I personally believe the interchangeability in some of the product profile (inaudible) we have biosimilar Humira really differentiates us and allow payers to think about actually switching and transferring patients a bit more easily than they would on other products that don't have those characteristics. But I'll let Sven answer a bit of that.

And then on the Gx, I'll take a stab of that as well. In the -- look, I obviously don't have history with this $1 billion comment. And so I can leave that behind from my perspective. What I would say is in the U.S., stability of our generics business should be driven about -- our pipeline what we launch when we launch and the ability to do that. And what we focused on and what we'll continue to focus on is complex generics. Now obviously, they have unpredictability, but when you do get them into the market, they are very profitable and sustainable.

So I think for me, it's not so much about getting back to a revenue number to not making sure you have a Gx business that is profitable, predictable and allows you to get growth in the right areas and that comes back to profitability.

But I'll hand over to Sven to give his view on those 2 questions.

Thanks, Gary. I think you were interested in Humira market formation and the benefit of interchangeability. So in what concerns market formation, I think we will go through 3 phases. Phase 1 is right now because Amgen already entered the market with a non-interchangeable Humira biosimilar. Then we have the next inflection point, which will be our market entry it's July 1. And then we see a clear transition towards biosimilars with the formulary changes that come in 2024. So there will be basically 3 phases for the Humira market formation.

I believe we are well positioned. We have discussions with all our customers on the July 1 date. Our customers very well recognized the importance of interchangeability, and I believe it has become even more important since FDA has guided to this year staying on formulary. And if you have EPI, the originator on formulary, of course, you need an interchangeable biosimilar to really drive uptake of biosimilar generics in this space.

And we also did recently market research on the question of pull-through with pharmacists and HCPs. And here, we also saw that interchangeability is actually well known in this professional community and especially HCPs look for interchangeability designation when writing biosimilar other than Humira. So I believe, overall, our product profile is quite strong. We have high concentration, citrate-free interchangeable product. We are working towards FDA approval. And for that reason, I believe we can participate in this Phase 2 market formation starting in July.

And adding to Richard's comments about the complex generics of the U.S. generics business and our run rate. So the run rate was $3.75 billion in 2021 and $3.55 billion in 2022. Our focus is now this year on creating a Humira success and, of course, to bring more complex generics to the market because what we've seen in our portfolio is despite the hurdles that you have for FDA approval with complex generics, they show themselves to be very resilient and drive longer-term value and especially when we look at our gross margin structure, you can see how important complex generics became over the last few years.

So for this year, we talk about, especially for Forteo as an opportunity, (inaudible) as a second opportunity and then the other complex generics that we also talked about in the previous years, such as Restasis or Simvastatin. And then we have a couple of other complex generics in the pipeline potentially to be launched in 2023 if we get FDA approval.

This is from the line of Glen Santangelo from Jefferies.

Eli, I just wanted to unpack the revenue guidance a little bit more, if I could. I mean essentially, last quarter, you guided fiscal '22 revenues of $14.8 million to $15.4 million. And now you're kind of just rolling that same guidance on '23. And obviously, you're building in some contributions from the growth in AUSTEDO and some risk-adjusted contributions from UZEDY and Humira. So I was wondering if you could just talk about the offsets to that -- to those numbers, to that growth. Will it be the same in '23 as it was in '22? Should we expect sort of a similar type of deceleration in the U.S. generics business and a similar type of runoff in COPAXONE? Or is there something else we should be thinking about, for example, like FX playing a bigger role?

Okay. Thank you, Glen, for the question. So a few dynamics in that range. First of all, if you look on the midpoint of 15.1%, you will see versus '22 kind of a modest growth, call it like a 2% and -- but this is based on a risk adjusted in terms of several launches mostly related with North America. Now if you think about the combination of AUSTEDO, AJOVY and COPAXONE, that's actually around $70 million higher than how we came in '22. And we believe that there is still modest opportunities both in AJOVY and AUSTEDO as we're actually running now the trend on the TRx. So that's one element.

And then a few other elements really related to our stabilized business in Europe in terms of generics and OTC. We see there also kind of a modest growth, and we live in kind of an environment which is very volatile in terms of FX, and we keep kind of enough spread in order to make sure that we're capturing any potential rebounding in terms of mostly on the euro appreciation versus dollars.

Okay. Maybe if I could just ask one quick follow-up question on the balance sheet. Richard. You sort of seem to suggest that debt reduction remains a primary focus, but how do you think more broadly about the leverage situation, right? Because as Eli sort of talked about in his prepared remarks, right, there's significant maturities coming up in the next sort of few years that are -- at or above the level of free cash flow you're generating now and ultimately, there's going to be some opioid payments that are going to have to be made. So how do you think about getting that debt down to those sort of 27 targets, just sort of given the current level of cash flow that you're generating, how should we think about that over the next couple of years in '23 in particular?

Thanks for that follow-on question, Glen. And what I'd say before I hand over to Eli is we think (technical difficulty) plan about our debt and repayment of the debt thoroughly and long term. So the way we think about some of the payments we have to pay in '23, '24 and '25, we've been working on for some time. So firstly, just to give you that background. And maybe, Eli, if you could go into more specifics about that.

Okay. Yes, Glen. So looking mostly on liquidity and free cash flow and the debt. So I will start by -- if you look on the guidance we gave for the free cash flow, 1.7 to the 2.1, that mid 1.9%, if you compare it to where we end at '22, call it, around 15% kind of a reduction. This is mostly related to the fact that we are considering coming back to the market to address our '25 maturity debt phase. And that means that we will -- according to the current interest rate environment, we'll need to step up in our fund expenses. So this element that I mentioned already (inaudible) out of this, I would say, a decrease.

Other elements according to the ongoing development with the time lines on the opioid settlement, we see ourselves paying the first payment, and that's actually modeled in our free cash flow generation into Q3 '23. And this is around incremental additional $300 million versus what we paid in '22. So this is kind of the dynamic on that midpoint. Now if you look on the lower end, it's actually 1.7 , part of the refinancing that we're planning in '23 actually planning to -- actually get a bit lower debt take for '23, '24, '25, to the level of 1.7, 1.8 in order to make sure that we have enough cushions to drive the business mostly because of those developments that I mentioned.

And as I mentioned in my prepared remarks, we have ongoing actions going on our working capital. That cash conversion improvement in the last 3 years mainly coming from those elements. So high level, in terms of liquidity, we see ourselves really strongly positioned in order to -- the ability to start the debt as well to meet our commitments in terms of obligations, mostly with the coming of settlement.

This is from the line of Jason Gerberry from Bank of America.

Just wanted to follow up on that free cash flow comment. I think that you used the term incremental for the $300 million of added opioid costs, but I think you had some payments for opioids in 2022. So should we think about that as like the $300 plus? What was kind of the run rate of payments in 2022? Or just the total of about $300 million of opioid-related payments.

And then on the '23 guidance element, I just wanted to ask the Humira question a little bit differently. So everybody is saying '23 is going to be more of a modest year of biosimilar Humira uptake. But if you were able to get the interchangeability, mindful that you're giving guidance on a risk-adjusted basis, but is there a big upside scenario? Or is it too early to say and you need to kind of get to July contracting before you can kind of comment on that.

Okay. Thank you, Jason. Thanks for the question. I think I'll hand you, obviously, the opioids and cash to Eli and then Sven can talk about the opportunity with Humira and some of the variables in that. So Eli, first.

Yes. So Jason, thanks for the questions. I will clarify. As you recall, we had already before getting to that mature development on the nationwide. We already stated that we settled. And during 2022, we paid already around $130 million in our free cash flow. And that amount will have kind of carry over of around $150 million for next year. Now this is not including the $200 million nationwide that we will need to pay in -- according to the current trajectory of the process in Q3 2023. So you can actually model around $430 million to $450 million that's going to be paid for opioid this year. Is it clear?

Yes, that's clear.

Yes, okay.

Okay, Humira. Our plan and the risk adjustment that we took. I think that was the topic. So first of all, we plan as having the interchangeable product in July, so that we get approval for it. Just as a reminder, the weekly process by the FDA for the interchangeable Humira from our partner Alvotech, has been concluded and the outstanding issue for people is now the site inspection that was scheduled for March 6. So we expect if the site inspection will be successful, we get approval for both BLAs that are with the FDA.

(technical difficulty)

The guidance that we have. So is there an upside? Of course, there's an upside if we sign all the contracts, and we have a limited number of competition within these contracts. We are quite confident that we can generate pull-through because of the product profile. But we have to wait and see for the next step, and I would say we take it step by step. We're quite confident in approval. We also are quite confident in our ability to supply the market with the required volumes. So that's all on track.

Jason, I know that we mean -- we were down for -- it's okay, is that what you need?

Yes.

This is from Balaji Prasad from Barclays.

Richard, you have articulated the importance of biosimilars for Teva over the next few years. And as I look at the long-term guidance that you provided of mid-single digits, I want to understand the role of specialty segments within this especially as we look at the pipeline and the late-stage assets in specialty as parts?

And secondly, coming to this year's guidance, excluding FX and biosimilars Humira, are there any other major variables which influenced the $600 million revenue of $400 million EBITDA spread?

Thanks for the question. I'll take the first part and then maybe tag team with Eli on the second part. So I think your question was around sort of drive growth to our specialty portfolio going forward. So let me sort of touch a bit upon that. I think I highlighted within the call already that the opportunity we still see around AUSTEDO and AJOVY. AUSTEDO particularly when you look about the patient numbers that still are not being treated, I think the opportunity is significant to bring that therapy to a lot more patients. So I see that as a major driver and AJOVY I see as a driver that can probably be worthwhile outside the U.S. as we expand more into Europe and then into international market because of the introduction of the oral therapies into the U.S.

But then I will touch upon the pipeline as well. So you said the risperidone product, we have olanzapine, that product that's gone into Phase 3 clinical trials. So I think -- and then we have our innovative pipeline which we'll talk about midyear, which I see more as the medium term. But excited about it. I think that could bring some significant growth going forward, obviously, if that gets through the clinical development phase. So I think we have a number of assets already. And that's not mentioned some of the complex generics that Sven spoke about earlier, which we're still waiting for FDA approval.

So I think we're well positioned with our pipeline across specialty, biosimilars and complex generics. Obviously, the challenge always is making sure we get those to markets in a timely fashion, and that's what we're going to be working hard on. Now with regard to the spread on the revenue, I'll let Eli take that and I think your comments are about you understand the FX, you understand the biosimilars, but what else is driving that. So Eli, if you could help you clarity that.

Yes. So Balaji, thanks for the question. Yes, when you drive the kind of range when you start the year, you look on -- mostly on programs that require (inaudible) adjustments. So in addition to Humira in the U.S. generics, we have a few of them that's risk adjusted. So they might come and be better than what we expect. So this is part of that range and also the -- there is a solid business that we have with Europe generics and OTC even considering, I would say, the average of current run rate in '22 that we see this one (technical difficulty) also with a great potential. So this is -- those 2 elements, I would say, are so part of those range.

This is from the line of Elliot Wilbur from Raymond James.

Maybe I could ask Sven to just follow up on the last question with respect to sort of the range of possibilities within the North American Generics segment in 2023 and specifically thinking about new product launch opportunities. If there's anything you can highlight in terms of date certain items or launches with certainty pursuant to settlements and then maybe specifically just some of the complex generics that could enter the equation in 2023. I know we've -- I feel like we've been talking about teriparatide and cyclosporine for 3 presidential administrations here. And obviously, the FDA has been slow on complex generics, but any additional clarity you could add there with respect to the new product dynamic in 2023 would be helpful.

And then for Richard, outside of the reiteration of the company's prior long-term financial targets, wondering if the strategic review or the updated strategic plan, in fact, could modify any of those parameters and thinking specifically about the 2027 debt-to-EBITDA target of 2x. Certainly seems like financial markets, equity holders will be much more comfortable with a higher leverage ratio, 2.5x to 3x and if they were comfortable with the company's use of discretionary capital in terms of pursuing pipeline enhancement initiatives in additional strategic investments. So I'm wondering if there's maybe some flexibility, particularly with respect to that parameter would free up quite a bit of cash flow for reinvestment into pipeline and longer-term growth assets.

Thanks for the 2 questions, Elliot, So look, I'll go in the order you deliver them. So I'll ask Sven to answer one and the almost complex generics approvals that you've been experiencing through the last 3 presidential campaign.

Yes. So the usual suspects, thanks for the question, Elliot. So U.S. generics this year, overall, we'll see a weak patent expiring year. So this year doesn't have a lot of, let's say, launches that are naturally driven by patent expiry dates. It will be more driven by FDA approvals and settlement entries. As you also pointed out, Humira, we already talked about. For TO, we received the [CRL] that we answered to the FDA. We are working with them closely to sort out this issue. Just as a reminder, this product has been launched many years ago in Europe already with EMA approval and we know how to manufacture it, of course. And I believe the product is high quality and that we will get the FDA around to give us approval.

Then we have the reentry of REVLIMID, of course, due to our settlement date that is working on an annual cycle. So when we reenter this market with a higher volume allocation within the settlement with BMS. And then we have, of course, [Xulane], which is a new drug on the list for launch this year. And then I have a couple of other products that we say, prepared for launch, assuming that we get FDA approval. But since we have made some experiences with the FDA about how difficult it is to get complex generics approved. I don't want to give you a certain, let's say, now I think once we get approval, we will communicate more around that.

But overall, I can say, let's say, complex generics are still quite attractive for us because if you analyze in the classical 80-20 analysis, our gross margin and the cash contribution within the generics portfolio, complex generics are certainly a major stabilizer in our business in North America. You also see that our price decline is quite stable in the base business. So that has improved over the last year, and we don't expect the organic changes in that space. So overall, I would say, U.S. generics will develop if we get all the approvals that we discuss on a regular basis in this call.

Thank you, Sven. And then to answer your question about the paying down debts and the EBITDA target we gave in 2027 and flexibility around that, if I heard you correctly Elliot. So look, we're in the midst of doing our strategic review and understanding our plan going forward. And that's a strategy that's going to deliver growth. That's the whole point of putting that strategy together. I think what we think is important and what is the team has worked hard on is to get credibility around our debt and all the payment of it over the last few years. And so we don't want to squander that too quickly.

So I think as we work through the strategic review and understand the opportunities and the need for capital both within the company to reallocate resources to drive some of our pipeline on our end market products as well as to do some video now. We need to think about that. But I'd also like to say that I think we have the ability to pay down that debt in the fashion that we've outlined and still be able to have some capital to allocate to drive the company back to growth. But we're in the midst of that, but I appreciate your point of view and your question to challenge that. And we'll be able to give a bit more clarity on that this year.

This is from the line of Chris Schott from JPMorgan.

Just 2 for me. I guess, first, maybe, Eli, how should we be thinking about gross margins this year. I know you're targeting flat OpEx, but just maybe a little bit more color on the components of OpEx as we think about '23?

And the second one was just kind of a bigger picture question on the biosimilar business. As you talked about this -- as this continues to ramp and it's an important growth driver for Teva. I guess there's a continued kind of partner-centric approach make the most sense for the company or would these be capabilities you would want to develop, I guess, to be more in-house over time as you think about kind of really trying to maximize the value of this opportunity.

Thanks, Chris. Thanks for the question. So Eli, you take the first one and then I can chime in with a few on the second.

Thanks Chris, for the question. So we end up; 22 around 54% gross margin. And actually, when we are looking on '23, we're going to see a bit higher, I would say, additional 0.3% and one of the things that we need to remember that the macroeconomic headwinds actually, overall, if you look on the numbers, it hit us around on our revenues to call it around $300 million with all the activities that we've already done and all those, I would say, optimization that were part of our long-term financial targets to expand our margin has helped us, as I mentioned in my prepared remarks, we partially offset the elements.

Now there is also a kind of element on revenue mix, and you can actually see that the with the growth of AUSTEDO and as well on AJOVY and a few other elements that we are actually working on. We're going to see a very modest increase but not more to the level of 54.5% I would say, in '23, which means that our ability to keep the current level on the OpEx will stay the same and the residual amount will flow through the OP margin.

Thanks, Eli. So on the biosimilars. So I think the question, Chris, was around as we move forward, we see it as a growth driver. Is this continued partner strategy or not. So firstly, let me clarify that although we have a good and productive partnership with Alvotech, which is delivering a nice pipeline. We also have, I think, it's 6 in-house biosimilars that we've developed ourselves.

And going back to a comment I made on an earlier question. What I think is important with biosimilars is that we have a broad and deep pipeline that we can address most of these large biologics when they come off patent. And to do that, to do that effectively from a capital allocation point of view, I think it's a combination. It's a combination of partnering and it's a combination of doing some things in-house. And so that's what I see going forward. That combination, just to make sure we have the right pipeline and we're launching the products at the right time.

And the last question is from Rishi Parekh from JPMorgan.

I just want to confirm a few things and then talk about -- or ask a few questions on your balance sheet. With regards to your free cash flow, that 1.7 to 2.1, I want to confirm that, that includes the $450 million of opioid payments? Or is it a different number?

Yes, it's including.

Okay. Great. And then with regards to your maturities, if I heard you correctly, I think you said that you're going to address your '23, '24 and '25 maturities, which is different than what you have said at the JPMorgan conference. I was hoping that you could just walk us through what led to that change? Is it something related to your free cash flow or something related just to the interest rate environment, but I would love to just have you walk through that.

Yes. So when we actually set the market, you will appreciate that the interest rate environment is higher than what we expected to tender on our debt take, and that means that we will have an impact on our -- that will flow through impact on our free cash flow. This is one. The second thing is that as we move forward and we see ourselves now more inside of positive momentum with the opioid, we actually want to make sure that we have enough cushion to manage that liability. And coming back to your first question, and that's actually already embedded there.

So we used to have kind of a 2.12, 1.9 range on the debt take, currently, the '23 is 2.1, '24 is 1.9. We're going to take it lower a bit in order to make sure that we have enough cushions there to manage it, and it will be part of the coming refinancing, which majority will be focused on the debt take of '25.

And then with the drop-down in your AR financing next year to $500 million, one, can you walk us through why it's declining by $500 million next year? And is that also affecting your thoughts around how you're looking to address your debt maturities this year?

Yes. So I don't understand the drop on the AR for next year. Where you're actually considering that one? But I can mention the dynamics. This year, in terms of working capital, we were able to optimize our outstanding tables as well a DSO. And that actually offset part of inventory increase in order to support our production plan for mostly for the first half of the year.

Yes. Sorry, I was just referring to the new AR facility that you entered into. I think it's $1 billion through November of this year, and then it drops to $500 million from November '23 onwards to November '25. And I was just hoping for an explanation behind that drop?

Yes. So actually, the facility is around $1 billion. We are not using the full of it. We use the 800 as an opportunity for us to be flexible on that program by actually initiating further enhancement on other elements under working capital that will allow us to be more flexible and you reduce that program going forward.

Okay. Great. I follow with my direct questions later.

Thank you for your questions. I'd like to thank everybody for the questions and interest in the call today. And I'd like to also apologize for some of the technical issues at the start. That's always out of our control, but I appreciate you bearing with us. And on that, I'd like to close the call. Once again, thank you for your interest and look forward to talking to you on future calls.

Thank you. This does conclude the conference for today. Thank you for participating, and you may now disconnect.